Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sulfonylureas improve neurological development in children with neonatal diabetes owing to potassium-channel mutations, supporting prompt diagnosis and early treatment with such agents, shows the first study of its kind.
The paper was published online in Diabetes Care October 5 by Jacques Beltrand, MD, PhD, from the Necker University Hospital for Sick Children, Paris, and colleagues and is the follow-up of two previous studies (Lancet Diabetes Endocrinol. 2013;1:199–207; N Engl J Med. 2006;355:467–477).
Senior author Michel Polak, MD, PhD, from the same institution, told Medscape Medical News that "glibenclamide [known as glyburide in the US] allows the definitive discontinuation of insulin and noticeably improves hypotonia, gesture conception, and realization and hyperactivity.
http://www.medscape.com/viewarticle/852621
The paper was published online in Diabetes Care October 5 by Jacques Beltrand, MD, PhD, from the Necker University Hospital for Sick Children, Paris, and colleagues and is the follow-up of two previous studies (Lancet Diabetes Endocrinol. 2013;1:199–207; N Engl J Med. 2006;355:467–477).
Senior author Michel Polak, MD, PhD, from the same institution, told Medscape Medical News that "glibenclamide [known as glyburide in the US] allows the definitive discontinuation of insulin and noticeably improves hypotonia, gesture conception, and realization and hyperactivity.
http://www.medscape.com/viewarticle/852621